英国のドライアイ市場レポート : 2027年までの予測

出版:Market Research Future(マーケットリサーチフューチャー) 出版年月:2022年6月

UK Dry Eye Market Report Forecast till 2027

ページ数 72
価格
シングルユーザライセンス USD2,950
エンタープライズライセンス USD5,250
種別 英文調査報告書

レポート目次    お問合せ・ご注文    価格・納期について

無料サンプル

UK dry eye market Forecast till 2027

Market Overview
The UK dry eye market is anticipated to register a significant CAGR of 3.93% to surpass USD 106.19 Million by the end of 2027. Dry eye is an ocular disorder caused by the lack of tear fluid to lubricate the eyes. This can be an indicator of either low production of tears or rapid evaporation of the film of tears on the surface of the eyes, which can be brought about by several conditions. The growth of the UK dry eye market can be attributed to the increasing number of the geriatric population prone to various eye disorders such as dry eye and the upsurge in the prevalence of disease conditions such as diabetes that affect the functioning of the eyes. A promising number of pipeline drugs for dry eye disease (DED) is another key factor driving the market growth. The aging population in the country has led to an increase in the prevalence of overall dry eye disease in the country.
The growth of the UK dry eye market is expected to be driven by the increasing aging population prone to various eye disorders, the rising prevalence of dry eye diseases, and novel treatment methods available for eye disorders. In addition, the promising treatment of Dry Eye Diseases (DED) and the rising number of laser surgeries are propelling the market growth in the UK. However, the dearth of skilled ophthalmologists, adverse reactions of products, and lack of awareness related to the disease are expected to restrict the market growth. However, the lack of awareness about the disease, self-medication by patients suffering from DED, and adverse effects from dry eye products are a few factors limiting the market growth of the UK dry eye market.
Furthermore, market players in the country are involved in new product launches, geography expansion, and acquisitions. For instance, in November 2020, Santen UK company launched an artificial tear product, and an online resource platform, my eye care. health, to tackle the UK’s growing burden of dry eye disease. Such product innovation by the company focused on the treatment of DED by the players in the country is propelling the market growth of the UK dry eye market.
Market Segmentation
The UK dry eye market is segmented into products, drugs, end-user, and regions. Based on product the market is further classified into Liquid Drops, Gel, Liquid Wipes, and Eye Ointment. The drug segment is classified into Artificial lubricant eye drops, anti-inflammatory drugs, and autologous serum eye drops. The end-user segment divides the market into Hospital Pharmacies, Retail Pharmacies, and others.
Major Players
The major players operating in the dry eye market are Otsuka pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc, Novartis AG, I-MED Pharma, Lenstore, and Vision Direct.


目次

TABLE OF CONTENT
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 RISING PREVALENCE OF DRY EYE DISEASE
4.2.2 PROMISING PIPELINE DRUGS FOR DRY EYE DISEASE
4.2.3 TECHNOLOGICAL ADVANCEMENTS AND EMERGENCE OF NOVEL DIAGNOSTIC TOOLS
4.3 RESTRAINTS
4.3.1 LIMITED AWARENESS RELATED TO DRY EYE DISEASE
4.3.2 ADVERSE REACTION FROM DRY EYE PRODUCTS AND NO PROPER CURE AVAILABLE
4.4 OPPORTUNITY
4.4.1 COLLABORATION OF MARKET PLAYERS
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION AND SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF BUYERS
5.2.3 THREAT OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTES
5.2.5 INTENSITY OF RIVALRY
5.3 COVID-19 IMPACT ANALYSIS
5.3.1 OVERVIEW
5.3.2 IMPACT ON MARKET GROWTH
5.3.3 IMPACT ON THE COUNTRY
5.3.4 IMPACT ON MAJOR PLAYERS
6 UK DRY EYE MARKET, BY PRODUCT
6.1 OVERVIEW
7 UK DRY EYE MARKET, BY DRUGS
7.1 OVERVIEW
8 UK DRY EYE MARKET, BY DISTRIBUTION CHANNEL
8.1 OVERVIEW
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPETITIVE BENCHMARKING
9.3 UK DRY EYE MARKET: COMPANY RANKING
9.4 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS
9.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
9.5.1 NEW PRODUCT LAUNCHES
9.5.2 ACQUISITIONS
9.6 FINANCIAL MATRIX
10 COMPANY PROFILES
10.1 OTSUKA PHARMACEUTICAL CO., LTD
10.1.1 COMPANY OVERVIEW
10.1.2 FINANCIAL OVERVIEW
10.1.3 PRODUCTS/SERVICES OFFERED
10.1.4 KEY DEVELOPMENTS
10.1.5 SWOT ANALYSIS
10.1.6 KEY STRATEGIES
10.2 SANTEN PHARMACEUTICAL CO., LTD
10.2.1 COMPANY OVERVIEW
10.2.2 FINANCIAL OVERVIEW
10.2.3 PRODUCTS/SERVICES OFFERED
10.2.4 KEY DEVELOPMENTS
10.2.5 SWOT ANALYSIS
10.2.6 KEY STRATEGIES
10.3 BAUSCH AND LOMB PVT LTD
10.3.1 COMPANY OVERVIEW
10.3.2 FINANCIAL OVERVIEW
10.3.3 PRODUCTS/SERVICES OFFERED
10.3.4 KEY DEVELOPMENTS
10.3.5 SWOT ANALYSIS
10.3.6 KEY STRATEGIES
10.4 ALLERGAN PLC
10.4.1 COMPANY OVERVIEW
10.4.2 FINANCIAL OVERVIEW
10.4.3 PRODUCTS/SERVICES OFFERED
10.4.4 KEY DEVELOPMENTS
10.4.5 SWOT ANALYSIS
10.4.6 KEY STRATEGIES
10.5 TEVA PHARMACEUTICAL INDUSTRIES LTD
10.5.1 COMPANY OVERVIEW
10.5.2 FINANCIAL OVERVIEW
10.5.3 PRODUCTS/SERVICES OFFERED
10.5.4 KEY DEVELOPMENTS
10.5.5 SWOT ANALYSIS
10.5.6 KEY STRATEGIES
10.6 JOHNSON & JOHNSON SERVICES INC.
10.6.1 COMPANY OVERVIEW
10.6.2 FINANCIAL OVERVIEW
10.6.3 PRODUCTS/SERVICES OFFERED
10.6.4 KEY DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.6.6 KEY STRATEGIES
10.7 NOVARTIS AG
10.7.1 COMPANY OVERVIEW
10.7.2 FINANCIAL OVERVIEW
10.7.3 PRODUCTS/SERVICES OFFERED
10.7.4 KEY DEVELOPMENTS
10.7.5 SWOT ANALYSIS
10.7.6 KEY STRATEGIES
10.8 I-MED PHARMA INC
10.8.1 COMPANY OVERVIEW
10.8.2 FINANCIAL OVERVIEW
10.8.3 PRODUCTS/SERVICES OFFERED
10.8.4 KEY DEVELOPMENTS
10.8.5 SWOT ANALYSIS
10.8.6 KEY STRATEGIES
10.9 LENSTORE
10.9.1 COMPANY OVERVIEW
10.9.2 FINANCIAL OVERVIEW
10.9.3 PRODUCTS/SERVICES OFFERED
10.9.4 KEY DEVELOPMENTS
10.9.5 SWOT ANALYSIS
10.9.6 KEY STRATEGIES
10.10 VISION DIRECT
10.10.1 COMPANY OVERVIEW
10.10.2 FINANCIAL OVERVIEW
10.10.3 PRODUCTS/SERVICES OFFERED
10.10.4 KEY DEVELOPMENTS
10.10.5 SWOT ANALYSIS
10.10.6 KEY STRATEGIES
11 APPENDIX
11.1 REFERENCES
11.2 RELATED REPORTS

LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
TABLE 3 UK: DRY EYE TREATMENT MARKET, BY PRODUCT, 2017–2027 (USD MILLION)
TABLE 4 UK: DRY EYE TREATMENT MARKET, BY DRUGS, 2017–2027 (USD MILLION)
TABLE 5 UK: DRY EYE TREATMENT MARKET, BY ARTIFICIAL LUBRICANT EYE DROPS TYPE, , 2017–2027 (USD MILLION)
TABLE 6 UK: DRY EYE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION)
TABLE 7 UK: E-COMMERCE DISTRIBUTION CHANNEL, BY SUB SEGMENT, 2017–2027 (USD MILLION)
TABLE 8 MAJOR MANUFACTURERS RANKING, 2019
TABLE 9 TOP PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE DRY EYE MARKET
TABLE 10 NEW PRODUCT LAUNCHES
TABLE 11 ACQUISITIONS
TABLE 12 OTSUKA PHARMACEUTICAL CO., LTD: PRODUCTS/SERVICES OFFERED
TABLE 13 SANTEN PHARMACEUTICAL CO., LTD: PRODUCTS/SERVICES OFFERED
TABLE 14 BAUSCH AND LOMB PVT LTD: PRODUCTS/SERVICES OFFERED
TABLE 15 ALLERGAN PLC: PRODUCTS/SERVICES OFFERED
TABLE 16 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS/SERVICES OFFERED
TABLE 17 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENTS
TABLE 18 JOHNSON & JOHNSON SERVICES INC.: PRODUCTS/SERVICES OFFERED
TABLE 19 NOVARTIS AG: PRODUCTS/SERVICES OFFERED
TABLE 20 NOVARTIS AG: KEY DEVELOPMENTS
TABLE 21 I-MED PHARMA: PRODUCTS/SERVICES OFFERED
TABLE 22 I-MED PHARMA: KEY DEVELOPMENTS
TABLE 23 LENSTORE: PRODUCTS/SERVICES OFFERED
TABLE 24 LENSTORE: KEY DEVELOPMENTS
TABLE 25 VISION DIRECT: PRODUCTS/SERVICES OFFERED

LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS
FIGURE 2 UK DRY EYE MARKET STRUCTURE
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 4 MARKET DYNAMICS OVERVIEW: UK DRY EYE MARKET
FIGURE 5 DRIVERS: IMPACT ANALYSIS
FIGURE 6 RESTRAINTS: IMPACT ANALYSIS
FIGURE 7 VALUE CHAIN: UK DRY EYE MARKET
FIGURE 8 PORTER’S FIVE FORCES ANALYSIS: UK DRY EYE MARKET
FIGURE 9 UK: DRY EYE TREATMENT MARKET, BY PRODUCT, 2019 & 2027 (USD MILLION)
FIGURE 10 UK: DRY EYE TREATMENT MARKET, BY DRUGS, 2019 & 2027 (USD MILLION)
FIGURE 11 UK: DRY EYE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019 & 2027 (USD MILLION)
FIGURE 12 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 13 SALES & OPERATING INCOME, 2019
FIGURE 14 R&D EXPENDITURE, 2019
FIGURE 15 OTSUKA PHARMACEUTICAL CO., LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 16 OTSUKA PHARMACEUTICAL CO., LTD: SWOT ANALYSIS
FIGURE 17 SANTEN PHARMACEUTICAL CO., LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 18 SANTEN PHARMACEUTICAL CO., LTD: SWOT ANALYSIS
FIGURE 19 BAUSCH AND LOMB PVT LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 20 BAUSCH AND LOMB PVT LTD: SWOT ANALYSIS
FIGURE 21 ALLERGAN PLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 ALLERGAN PLC: SWOT ANALYSIS
FIGURE 23 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 24 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS
FIGURE 25 JOHNSON & JOHNSON SERVICES INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 26 JOHNSON & JOHNSON SERVICES INC.: SWOT ANALYSIS
FIGURE 27 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 NOVARTIS AG: SWOT ANALYSIS
FIGURE 29 I-MED PHARMA: SWOT ANALYSIS
FIGURE 30 LENSTORE: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 LENSTORE: SWOT ANALYSIS
FIGURE 32 VISION DIRECT: SWOT ANALYSIS


    お問合せフォーム

    • レポートのタイトルは自動で入ります。
    • *のある項目は必須項目です。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com